Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with squamous non-small cell lung cancer (a specific type of lung cancer), confirmed by a laboratory test on a tissue or cell sample.
• People whose lung cancer has spread to other parts of the body (Stage IV) and cannot be treated with the aim of a cure.
• People whose cancer testing has not found any specific gene changes (mutations) for which there are already approved targeted treatments available locally.
• People whose tumor sample shows a certain level of a protein called PD-L1 (at least 1% of tumor cells), confirmed by an acceptable tissue sample provided to the trial.
• People who have at least one measurable tumor that has not been previously treated with radiation, large enough to be accurately measured by CT or MRI scan.
• People whose organs (such as kidneys and liver) and bone marrow are functioning well enough to meet the trial's requirements.

Who may not be able to join:

• People whose lung cancer includes certain subtypes called small cell or neuroendocrine components.
• People who have cancer that has spread to the brain, unless those brain metastases are not causing symptoms, are stable, and have not required steroids or seizure medications for at least 7 days before joining — and at least 2 weeks must have passed since any brain radiation or surgery, with full recovery from side effects (confirm with trial site).
• People who have previously received any systemic (whole-body) treatment for advanced or metastatic lung cancer.
• People who have previously been treated with a type of immunotherapy known as an anti-PD-1 or anti-PD-L1 drug.
• People who have previously received a treatment targeting a pathway called TIGIT, or any other cancer therapy that works by targeting immune-regulatory pathways.
• People with a history of another cancer diagnosis, unless that cancer was treated with the aim of a cure, has shown no signs of returning for at least 2 years, and is considered low risk for coming back.
• People with active or previously diagnosed autoimmune or inflammatory conditions that have required ongoing treatment with steroids or other immune-suppressing medications.
• People with an active condition that weakens the immune system, or an active serious infection.
• People with an active tuberculosis infection.

Important: Always verify eligibility with the trial site directly before applying.